Evaluation of cognitive, affective, olfactory functions and sleep disturbance improvement in Dementia with Lewy Bodies patients treated with Galantamine

Evaluation of cognitive, affective, olfactory functions and sleep disturbance improvement in Dementia with Lewy Bodies patients treated with Galantamine - Evaluation of cognitive, affective, olfactory function and sleep disturbance improvement in DLB patients treated with Galantamine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022860

Enrollment

Registered

2016-06-23

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DLB patients

Interventions

We evaluate Galantamine in 8mg/day at first 4 weeks. After that, dosage increased 16mg/day. Conrol patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: DLB patients in our department who agreed to join our clinical trial

Exclusion criteria

Exclusion criteria: Patients treated with arrhythmia, epilepsy, bronchial asthma and severe obstructive uropathy. In addition, patients who occureed side effect of Galantamine during this clinical reseach

Design outcomes

Primary

Measure	Time frame
Evaluation of MMSE, HDS-R and FAB scores improvement after 1,3,6,9,12,15 months from dosage started	—

Countries

Japan

Contacts

Public ContactMami Takemoto

Okayama Unversity Neurology

takemoto.demekin@gmail.com086-235-7365

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026